This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waldhauer, I. Articles by Steinle, A. Search for Related Content PubMed PubMed Citation Articles by Waldhauer, I. Articles by Steinle, A.

Tumor-Associated MICA Is Shed by ADAM Proteases

¹ Institute for Cell Biology, Department of Immunology, Eberhard-Karls-University, Tübingen, Germany and ² Institute for Pharmacology and Toxicology, University Hospital RWTH Aachen, Aachen, Germany

Requests for reprints: Alexander Steinle, Institute for Cell Biology, Department of Immunology, Eberhard-Karls-University, Auf der Morgenstelle 15, D-72076 Tübingen, Germany. Phone: 49-7071-2980992; Fax: 49-7071-29-5653; E-mail: alexander.steinle{at}uni-tuebingen.de.

Key Words: MICA • NK cells • NKG2D • ADAM • tumor immunity

The immunoreceptor NKG2D promotes immunosurveillance of malignant cells and protects the host from tumor initiation by activating natural killer cells and costimulating CD8 T cells. NKG2D-mediated recognition of malignant cells by cytotoxic lymphocytes is enabled through the tumor-associated expression of NKG2D ligands (NKG2DL) resulting from cellular or genotoxic stress. Shedding of NKG2DL is thought to constitute a major countermechanism of tumor cells to subvert NKG2D-mediated immunosurveillance. Here, we report that the prototypical NKG2DL MICA is released by proteolytic cleavage in the stalk of the MICA ectodomain, where deletions, but not alanine substitutions, impede MICA shedding. Small compound-mediated stimulation and inhibition of MICA shedding adduced characteristics that indicated an involvement of members of the "a disintegrin and metalloproteinase" (ADAM) family. Accordingly, MICA shedding by tumor cells was inhibited by silencing of the related ADAM10 and ADAM17 proteases, which are known to promote tumor growth by releasing epidermal growth factor receptor ligands. Collectively, our data show that ADAM10 and ADAM17 are critically involved in the tumor-associated proteolytic release of soluble MICA facilitating tumor immune escape. Hence, therapeutic blockade of ADAM10 and ADAM17 seems promising for cancer treatment by targeting both growth and immune escape of tumors. [Cancer Res 2008;68(15):6368–76]

This article has been cited by other articles:

				K. Kohga, T. Takehara, T. Tatsumi, T. Miyagi, H. Ishida, K. Ohkawa, T. Kanto, N. Hiramatsu, and N. Hayashi Anticancer Chemotherapy Inhibits MHC Class I-Related Chain A Ectodomain Shedding by Downregulating ADAM10 Expression in Hepatocellular Carcinoma Cancer Res., October 15, 2009; 69(20): 8050 - 8057. [Abstract] [Full Text] [PDF]

				A. Paschen, A. Sucker, B. Hill, I. Moll, M. Zapatka, X. D. Nguyen, G. C. Sim, I. Gutmann, J. Hassel, J. C. Becker, et al. Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B Clin. Cancer Res., August 15, 2009; 15(16): 5208 - 5215. [Abstract] [Full Text] [PDF]